Biodexa Pharmaceuticals PLC (BDRX) Actualités

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Biodexa Announces Appointment of Precision for Medicine LLC as CRO for European Component of Phase 3 Study of eRapa in FAP

March 6, 2025 Biodexa Announces Appointment of Precision for Medicine LLC as CRO for European Component of...

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Biodexa Announces Allowance of U.S. Patent Covering Oral Rapamycin Nanoparticle Preparations (“eRapa”) and Use

February 24, 2025 Biodexa Announces Allowance of U.S. Patent Covering Oral Rapamycin Nanoparticle Preparations...

Form SCHEDULE 13G - Statement of Beneficial Ownership by Certain Investors

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Biodexa Receives US FDA Fast Track Designation for eRapa in Familial Adenomatous Polyposis

February 10, 2025 Biodexa Receives US FDA Fast Track Designation for eRapa in Familial Adenomatous Polyposis...

Form 424B3 - Prospectus [Rule 424(b)(3)]

Form EFFECT - Notice of Effectiveness

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Biodexa Strengthens Management Team - Appointment of Dr Gary A. Shangold as Chief Medical Officer

January 22, 2025 Biodexa Strengthens Management Team Appointment of Dr Gary A. Shangold as Chief Medical...

Form 424B3 - Prospectus [Rule 424(b)(3)]

Form 424B3 - Prospectus [Rule 424(b)(3)]

Form 424B3 - Prospectus [Rule 424(b)(3)]